Side-by-side · Research reference

TB-500vsThymosin α-1

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2Reviewed8/46 cited

BPhase 3Reviewed8/39 cited

TB-500

Thymosin β4 fragment · Healing

2 mgPer doseGoldstein 2012

Phase 2Evidence levelGoldstein 2012

~2 hrHalf-life

SQ or IM · Multiple sites · 2–3×/week

Thymosin α-1

Immune modulator · Approved (some countries)

1.6 mgPer doseIyer 2007

Phase 3Evidence levelIyer 2007 Camerini 2001

~2 hrHalf-life

SQ · 2× weekly · 6+ months for chronic indications

01Mechanism of Action

Parameter

TB-500

Thymosin α-1

Primary target

G-actin (sequestering) + cell-surface integrinsGoldstein 2012

Toll-like receptor 9 (TLR9) + T-cell maturation pathwayCamerini 2001

Pathway

Actin remodelling → cell migration; integrin-linked signaling → angiogenesis; anti-inflammatory cytokine modulationGoldstein 2012 Malinda 1999

TLR9 activation → ↑ IFN-α + IL-2 + IFN-γ → enhanced T-cell function + dendritic cell maturationIyer 2007

Downstream effect

Accelerated wound healing, endothelial migration, hair follicle regeneration, cardiac repair (preclinical)Goldstein 2012

Restored T-cell function, improved viral clearance, anti-tumour adjuvant effectsIyer 2007

Feedback intact?

Endogenous protein at baseline; supplementation amplifies

—

Origin

17-AA active fragment of endogenous 43-AA thymosin β4 (TMSB4X gene)Goldstein 2012

Synthetic 28-AA peptide identical to natural Tα-1 isolated from thymus extractCamerini 2001

Antibody development

—

02Dosage Protocols

Parameter

TB-500

Thymosin α-1

Standard dose

2 mg per injectionGoldstein 2012

Anecdotal community range; clinical Phase 2 trials used 70–840 mcg/kg IV.

—

Frequency

2× per week (loading); then 1× per week (maintenance)

2× weekly (Mon/Thu typical)

Lower / starter dose

1 mg per injection

0.8 mg per injection

Evidence basis

Animal-strong + Phase 2 dermal/ocular trialsGoldstein 2012

Phase 3 + approved (35+ countries as Zadaxin)Iyer 2007

Duration

4–8 weeks loading; longer maintenance for chronic injury

6–12 months for chronic indications

Reconstitution

Bacteriostatic water, 1–2 mL per 5 mg vial

Sterile water for injection per vial label

Timing

Evening or pre-rest preferred (anecdotal)

No specific time

Half-life

~2 hours (estimated; tissue uptake longer)

~2 hours plasma; tissue effect days

Standard dose (HBV/HCV)

—

1.6 mg SQ 2× weekly × 6–12 monthsIyer 2007

04Side Effects & Safety

Parameter

TB-500

Thymosin α-1

Injection site reaction

Mild erythema, transient pain

Erythema, mild discomfort

GI symptoms

Rare nausea (anecdotal)

Rare nausea

Cancer risk

Theoretical via angiogenesis pathway

No signal — used as adjuvant in oncology

Lethargy / fatigue

Reported anecdotally during loading phase

—

Antibody formation

No data (no long-term human trials)

—

Pregnancy / OB

Avoid

Long-term safety

Unknown beyond Phase 2

—

Fatigue

—

Common during initial weeks

Fever / flu-like

—

Mild interferon-like response possible

Autoimmune

—

Theoretical risk; caution in active autoimmune disease

Absolute Contraindications

TB-500

·Active malignancy (theoretical angiogenesis concern)
·Pregnancy / breastfeeding

Thymosin α-1

·Pregnancy / breastfeeding
·Hypersensitivity to peptide
·Concurrent immunosuppressant therapy (transplant patients)

Relative Contraindications

TB-500

·Cancer history
·Concurrent VEGF inhibitor therapy

Thymosin α-1

·Active autoimmune disease
·Severe immunocompromised state without supervision

05Administration Protocol

Parameter

TB-500

Thymosin α-1

1. Reconstitution

Add 1–2 mL bacteriostatic water to 5 mg vial → 2.5–5 mg/mL. Roll gently.

Add 1 mL sterile water per 1.6 mg vial → 1.6 mg/mL.

2. Injection site

SQ near injury site (preferred), or systemic SQ (abdomen). Rotate sites.

SQ — abdomen, thigh, or upper arm. Rotate sites.

3. Timing

Evening or pre-sleep is most common anecdotal timing.

2× weekly, e.g. Monday + Thursday.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.

Lyophilised: refrigerate. Reconstituted: refrigerate, use within 24 h.

5. Needle

27–31G, 4–8 mm insulin syringe.

06Stack Synergy

TB-500

+ BPC-157

Strong

View BPC-157 →

TB-500 and BPC-157 cover complementary halves of tissue repair: BPC-157 upregulates VEGFR2-driven angiogenesis and fibroblast outgrowth; TB-500 sequesters G-actin to enable endothelial / epithelial migration. The anecdotal canonical "healing stack" — pairs especially well for tendon and ligament injuries.

TB-500: 2 mg SQ · 2× per week
BPC-157: 250–500 mcg SQ · daily
Primary benefit: Combined angiogenesis + cell migration for tendon/ligament/muscle repair

Thymosin α-1

— no documented stacks